SGI-DNA Launches Automated Cloning Module For The BioXp 3200 System And Reaches Another Instrument Milestone

LA JOLLA, Calif., Jan. 13, 2016 /PRNewswire/ -- SGI-DNA, a Synthetic Genomics, Inc. (SGI) company, announced today that the world's first DNA printer, the BioXp 3200 System, has reached another milestone with the release of the BioXp cloning module. The addition of the cloning module to the instrument repertoire further solidifies SGI-DNA as an industry leader at the forefront of synthetic biology innovations and solutions. Users of the BioXp System cloning module may focus on DNA analytics and discovery, instead of the traditional time- and labor-intensive steps involved in DNA cloning. Simply stated, the BioXp System automates and expedites DNA cloning, a procedure used in nearly every academic and commercial molecular biology laboratory worldwide.

BioXp 3200 System

BioXp 3200 SystemCapabilities

The BioXp genomic workstation generates high-quality, linear DNA fragments from custom designed oligonucleotide pools and reagents. Now, with the introduction of the cloning module, the BioXp System has the additional capability to simultaneously deliver up to 24 circular DNA clones from custom DNA sequences. The launch of this first-of-its-kind module allows researchers to obtain cloned de novo DNA fragments in the laboratory virtually hands-free, further automating and shortening molecular biology work flows.

Julie Robinson, SGI Senior Product Manager comments, "In just 9 months, since the BioXp System was first launched, SGI-DNA is delivering on its stated plan to expand instrument capabilities. Our more than 25 life science research laboratory customers throughout the United States can upgrade their systems seamlessly over the internet without any hardware changes.  This scalable design is at the heart for the BioXpsystem.  By launching the cloning module SGI-DNA is moving from early access to full launch of the BioXp 3200 System."

BioXp 3200 System Future Plans

The instrument's multifunctional deck enables the machine to be upgraded to automate molecular biology workflows even more fully over time. Currently customers can order the machine, have it installed, and begin making DNA clones in a matter of weeks. SGI-DNA works closely with customers to optimize their use of the machine and has a complete line of DNA synthesis products and services which complement the BioXp 3200 System.

Due to its novelty and flexibility of use, the BioXp System was awarded Frost & Sullivan's 2015 New Product Innovation Award for Synthetic Biology. The instrument also received CE Mark certification in 2015, allowing it to be sold in Europe, with plans to launch the product overseas in 2016. The adoption of the instrument at several leading biotechnology companies, government laboratories, and research institutions portends that global demand for the BioXp3200 System will be strong.

About Synthetic Genomics

Synthetic Genomics Inc. (SGI) is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including developing new synthetic DNA products, tools and instruments through SGI-DNA, a wholly owned subsidiary of SGI. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Hamilton Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to accelerate the pace of synthetic biology discovery and innovation.

Oliver Fetzer, Ph.D., MBA, chief executive officer of Synthetic Genomics, Inc., will provide a corporate overview and presentation at the J.P. Morgan 34th Annual Healthcare Conference on Wednesday, January 13, 2016 at 1:00 p.m. ET (10:00 a.m. PT) in San Francisco, California.

For more information about our latest advances and the award-winning BioXp 3200 Instrument, please visit

SGI-DNA, a Synthetic Genomics, Inc. company

Photo -
Logo -


To view the original version on PR Newswire, visit:


Back to news